Compare General Dynamics Corporation (GD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? General Dynamics Corporation trades at $338.85 (market cap $89.94B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: General Dynamics Corporation is far larger — about 18.4× Travere Therapeutics Inc. Common Stock's market cap, and General Dynamics Corporation pays a 1.91% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 86 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GD | TVTX | |
|---|---|---|
Market Cap | $89.94B | $4.88B |
Volume | 1,284,020 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $395.97 | $67.52 |
52-Week Low | $312.53 | $26.79 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $95.08B | $5.01B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $334.66, down 0.24% with bearish technical signals despite strong fundamentals. The defense contractor shows robust revenue growth, increasing from $47.7B in 2024 to $52.5B in 2025, with consistent earnings beats. Analyst consensus remains bullish with a $414.57 price target, supported by strong Pentagon spending and dividend stability.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.27) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend champion status provide downside protection. Upside potential exists if technical resistance at $337 is breached.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
